New Zealand - English - Medsafe (Medicines Safety Authority)

eli lilly and company (nz) limited - erythromycin estolate 720mg equivalent to 500 mg erythromycin base;  ;   - tablet - 500 mg - active: erythromycin estolate 720mg equivalent to 500 mg erythromycin base     excipient: erythrosine   glycerol hyprolose hypromellose magnesium stearate methanol methylated spirits methylene chloride purified water quinoline yellow starch sunset yellow fcf titanium dioxide trichloroethane white beeswax

United States - English - NLM (National Library of Medicine)

parsolex gmp center, inc. - cycloserine (unii: 95ik5ki84z) (cycloserine - unii:95ik5ki84z) - cycloserine 250 mg in 250 mg - seromycin is indicated in the treatment of active pulmonary and extrapulmonary tuberculosis (including renal disease) when the causative organisms are susceptible to this drug and when treatment with the primary medications (streptomycin, isoniazid, rifampin, and ethambutol) has proved inadequate. like all antituberculosis drugs, seromycin should be administered in conjunction with other effective chemotherapy and not as the sole therapeutic agent. seromycin may be effective in the treatment of acute urinary tract infections caused by susceptible strains of gram–positive and gram–negative bacteria, especially enterobacter  spp. and escherichia coli . it is generally no more and is usually less effective than other antimicrobial agents in the treatment of urinary tract infections caused by bacteria other than mycobacteria. use of seromycin in these infections should be considered only when more conventional therapy has failed and when the organism has been demonstrated to be susceptib

United States - English - NLM (National Library of Medicine)

parsolex gmp center, inc. - cycloserine (unii: 95ik5ki84z) (cycloserine - unii:95ik5ki84z) - indications and usage seromycin ® is indicated in the treatment of active pulmonary and extrapulmonary tuberculosis (including renal disease) when the causative organisms are susceptible to this drug and when treatment with the primary medications (streptomycin, isoniazid, rifampin, and ethambutol) has proved inadequate. like all antituberculosis drugs, seromycin ® should be administered in conjunction with other effective chemotherapy and not as the sole therapeutic agent. seromycin ® may be effective in the treatment of acute urinary tract infections caused by susceptible strains of gram- positive and gram-negative bacteria. use of seromycin ® in these infections should be considered only when more conventional therapy has failed and when the organism has been demonstrated to be susceptible to the drug. contraindications administration is contraindicated in patients with any of the following: • hypersensitivity to seromycin

Nigeria - English - NAFDAC (National Agency for Food and Drugs Administration and Control)

erythromycin 250mg

New Zealand - English - Medsafe (Medicines Safety Authority)

eli lilly and company (nz) limited - erythromycin estolate 360mg equivalent to 250 mg erythromycin base;   - tablet - 250 mg - active: erythromycin estolate 360mg equivalent to 250 mg erythromycin base  

India - English - Central Drugs Standard Control Organization

astrum hc. - polymyxin b sulph. - inj - 500,000u. - vial

New Zealand - English - Medsafe (Medicines Safety Authority)

eli lilly and company (nz) limited - erythromycin estolate 360mg equivalent to 250 mg erythromycin base;   - capsule - 250 mg - active: erythromycin estolate 360mg equivalent to 250 mg erythromycin base   excipient: erythrosine gelatin   hydrated silica iron oxide red iron oxide yellow liquid paraffin magnesium stearate opacode purified talc quinoline yellow tekprint black sw-9008 titanium dioxide   water  

New Zealand - English - Medsafe (Medicines Safety Authority)

eli lilly and company (nz) limited - erythromycin estolate 36 mg/ml equivalent to 25 mg/ml erythromycin base;   - oral suspension - 125 mg/5ml - active: erythromycin estolate 36 mg/ml equivalent to 25 mg/ml erythromycin base   excipient: citric acid monohydrate dimeticone dispersible cellulose imitation orange juice methyl hydroxybenzoate propyl hydroxybenzoate purified water sodium calcium edetate sodium chloride sodium citrate dihydrate sodium laurilsulfate sucrose sunset yellow fcf

New Zealand - English - Medsafe (Medicines Safety Authority)

eli lilly and company (nz) limited - erythromycin estolate 72 mg/ml equivalent to 50 mg/ml erythromycin base;   - oral suspension - 250 mg/5ml - active: erythromycin estolate 72 mg/ml equivalent to 50 mg/ml erythromycin base   excipient: citric acid monohydrate dimeticone dispersible cellulose imitation 0range juice methyl hydroxybenzoate propyl hydroxybenzoate purified water sodium calcium edetate sodium chloride sodium citrate dihydrate sodium laurilsulfate sucrose sunset yellow fcf

Egypt - English - EDA (Egyptian Drug Authority)

el nile. - syrup